Risks and limits of Longevity Senioren

The risks and limits of longevity tests for seniors are substantial. Direct-to-consumer (DTC) tests like the MyBody-X DNA Longevity Test often promise personalized anti-aging strategies but are based on weak evidence. Polygenic risk scores for longevity explain only a tiny fraction of actual lifespan variance (<10%) and are not clinically actionable. Moreover, age-specific reference ranges are lacking—what is 'optimal' for a 30-year-old may be irrelevant or misleading for a 70-year-old. Overinterpretation is a major risk: a low polygenic score can create false reassurance, while a high score may cause unnecessary anxiety or dangerous self-experimentation (e.g., unmonitored hormone use). These tests are not diagnostic and cannot replace a medical workup. In seniors, especially those on multiple medications, interactions with supplements or hormones can be harmful. The evidence is predominantly marketing, not robust science. Seniors should view such tests as general insights only, always discussed with a healthcare provider.